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Abstract
Objective Cerebrospinal fluid (CSF) biomarkers are shown
to facilitate a risk identification of patients with mild
cognitive impairment (MCI) into different risk levels of
progression to Alzheimer’s disease (AD). Knowing a
patient’s risk level provides an opportunity for earlier
interventions, which could result in potential greater ben-
efits. We assessed the cost effectiveness of the use of CSF
biomarkers in MCI patients where the treatment decision
was based on patients’ risk level.
Methods We developed a state-transition model to project
lifetime quality-adjusted life-years (QALYs) and costs for
a cohort of 65-year-old MCI patients from a US societal
perspective. We compared four test-and-treat strategies
where the decision to treat was based on a patient’s risk
level (low, intermediate, high) of progressing to AD with
two strategies without testing, one where no patients were
treated during the MCI phase and in the other all patients
were treated. We performed deterministic and probabilistic
sensitivity analyses to evaluate parameter uncertainty.
Results Testing and treating low-risk MCI patients was the
most cost-effective strategy with an incremental cost-ef-
fectiveness ratio (ICER) of US$37,700 per QALY. Our
results were most sensitive to the level of treatment
effectiveness for patients with mild AD and for MCI
patients. Moreover, the ICERs for this strategy at the 2.5th
and 97.5th percentiles were US$18,900 and US$50,100 per
QALY, respectively.
Conclusion Based on the best available evidence regarding
the treatment effectiveness for MCI, this study suggests the
potential value of performing CSF biomarker testing for
early targeted treatments among MCI patients with a nar-
row range for the ICER.
Key Points for Decision Makers
Treating MCI patients at low risk generated greater
benefits, although it may be counterintuitive.
With a high degree of uncertainty, the decision of
whether to treatment MCI patients or not based on
their risk levels may benefit from gathering more
information on the treatment effectiveness for MCI.
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1 Introduction
Alzheimer’s disease (AD) is a devastating neurodegener-
ative disease that impairs memory, thought, and behavior;
reduces quality of life; and decreases survival. As more
people live long enough to become at-risk [1, 2], identi-
fying patients early in the disease continuum for greater
benefits from the potential interventions may alleviate
some of the burden on patients, caregivers, and society
[3, 4].
Prior to AD diagnosis, most patients progress through a
prodromal stage called mild cognitive impairment (MCI)
[5], which is a stage characterized by early memory loss
but with relatively well-preserved activities of daily living.
On average, MCI patients face a 10–15% risk of progres-
sion to AD each year [5–10]. Identifying patients at risk for
progression to AD at an earlier stage provides an oppor-
tunity to make decisions about disease management plans
and financial arrangements while cognitive function is still
capable [11, 12], and to access interventions with disease-
modifying effects if they were to become available
[13, 14].
Cerebrospinal fluid (CSF), consisting of a concentration
of Ab1–42 (a biomarker of amyloid b deposition in the
brain), total tau, and phosphorylated tau proteins [15, 16],
are shown to facilitate the identification of MCI patients
who are at different risk levels of progression to AD
[13, 17–19] and are included in the currently proposed
diagnostic criteria for AD [13] and MCI [20]. Moreover,
they are also considered the most preferred biomarkers for
studying disease progression due to their unique clinical
features and low incidences of complications [21, 22].
Accordingly, several multidisciplinary working groups
have either recommended using CSF biomarkers in the
diagnostic workup of MCI patients [23] or proposed the
utilization of CSF biomarkers in informing the likelihood
of the progression to AD among MCI patients [4, 24].
There is currently no cure for AD. With a hypothetical
disease-modifying therapy (DMT), however, data from
several simulation models supported the benefits of early
identification at the prodromal or predementia stage using
various diagnostic tools such as florbetaben positron emis-
sion tomography [25], brain magnetic resonance imaging
[26], apolipoprotein e4 genetic test [27], or CSF biomarkers
[28, 29]. In addition, some models compared the strategy of
a DMT versus the strategy of no DMT in patients with MCI
(the decision to treat or not was not based on the testing
results) [30, 31]; others compared different diagnostic
strategies with these novel testing techniques as an add-on
to standard diagnostic procedures [25, 26, 28].
The potential value of these tools to facilitate the
detection of AD at an early phase is only considered
speculative [14] due to the scant evidence pertaining to the
effectiveness of existing treatments for MCI patients. Yet,
results of a randomized clinical trial (RCT) [32] and meta-
analysis studies [33–37] showed the potential benefits of
cholinesterase inhibitors (ChEIs; e.g., donepezil, galan-
tamine, and rivastigmine) to delay the progression from
MCI to AD. Additionally, it is suggested by the recent
revision of cost-effectiveness analysis (CEA) recommen-
dations [38] that if a decision must be made (in our case
whether or not to intervene for MCI patients based on their
CSF biomarker test results), it should be made based on the
data availability. Given the clinical utility of CSF
biomarkers and the best available data on treatment
effectiveness, therefore, the objective of our study was to
determine the potential value of the use of CSF biomarker
testing in MCI patients by comparing various test-and-treat
strategies with strategies without test information. Here,
CSF biomarkers were used as a risk-stratification tool to
categorize patients into different risk levels of progression
to AD (instead of a diagnostic tool to dichotomize patients
into positive or negative testing results), and the decision to
treat was based on a patient’s risk level.
2 Methods
We developed a state-transition model to estimate the
costs, quality-adjusted life-years (QALYs), and cost
effectiveness of performing one-time CSF biomarker test-
ing for a cohort of 65-year-old MCI patients and then
treating some of these patients with ChEIs based on their
biomarker test results. We used evidence from a primary
data analysis [19] and the published literature to derive
relevant parameters. Costs and health outcomes were dis-
counted 3% annually per the US recommendation [39], and
the model cycle length was 1 year. We adopted a US
societal perspective and a lifetime horizon.
2.1 Model Structure
Figure 1 illustrates the model structure. MCI patients who
undergo biomarker testing are assigned a high-, interme-
diate-, or low-risk score that determines their risk of pro-
gressing to AD [19]. On the basis of this score, a subset of
patients would be treated with ChEI therapy in the MCI
stage. Providing treatment in this phase introduces a cost
and imposes a risk of experiencing side effects but also
might reduce a patient’s risk of developing AD. If MCI
patients progress to AD, whether treated or not, they pro-
gress through a series of health states defined by AD
severity (mild, moderate, or severe) and residential settings
(community or nursing home). Each year, patients are
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allowed to transition to another health state (progress in
severity or transition to nursing home), remain in the same
health state, or die. Once AD patients enter a nursing home
we assumed that they would remain in the institution until
death [40], given that most patients entering the nursing
home have severe AD.
2.2 Treatment Strategies
Because MCI patients could be categorized into one of
three risk levels of progression to AD based on their CSF
biomarker testing results (a positive and ordinal relation-
ship), we evaluated six test-and-treat strategies as follows:
1. No testing and no MCI treatment Treat only when MCI
patients convert to AD and stop treatment when they
progress to the severe stage.
2. Test and treat high risk Test MCI patients and only
treat those with a high-risk result until AD conversion;
no treatment for low- and intermediate-risk patients
until they convert to AD and stop treatment when they
progress to the severe stage.
3. Test and treat high or intermediate risk Test MCI
patients and treat those with a high- or intermediate-
risk result until AD conversion; no treatment for low-
risk patients until they convert to AD and stop
treatment when they progress to the severe stage.
4. Test and treat low risk Test MCI patients and treat
those with a low-risk result until AD conversion; no
treatment for high- and intermediate-risk patients until
they convert to AD and stop treatment when they
progress to the severe stage.
5. Test and treat low or intermediate risk Test MCI
patients and treat those with a low- or intermediate-risk
result until AD conversion; no treatment for high-risk
patients until they convert to AD and stop treatment
when they progress to the severe stage.
6. No testing and treat all MCI patients Treat all MCI
patients and stop treatment when patients convert to
AD.
Because evidence on the treatment effectiveness for
MCI patients is indefinite, we assumed that if MCI patients
received treatment, they would not be eligible for ChEI
treatment if they converted to AD based on clinical expert
opinion. We tested this assumption in the sensitivity
analysis.
2.3 Model Parameters
Table 1 summarizes the parameter estimates and their 95%
confidence intervals (CIs) if available. Otherwise, we used
50% higher or lower than the mean as the upper bound and
lower bound for the parameter estimate [41].
2.3.1 Disease Progression
In previous work [19], we estimated annual transition
probabilities from MCI to AD for each risk group (high,
intermediate, and low) defined by CSF biomarker levels
using 6-year follow-up data from the Alzheimer’s disease
Neuroimaging Initiative with 195 MCI patients. In brief,
time-dependent receiver operator characteristic analysis
was used to choose the best combination of CSF
biomarkers on the longitudinal predictive ability for the
progression of AD for MCI patients. Baseline CSF bio-
marker levels were summarized into a multi-biomarker
score by multiplying the biomarker level with each of their
own coefficients ([-0.006] 9 Ab1–42 ? 0.012 9 P-
tau181p) [19], derived from the fitted Cox proportional
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cerebrospinal fluid, MCI mild cognitive impairment, NH nursing home, Rx treatment
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Table 1 Parameter inputs for the state-transition model
Parameter Mean 95% CI Distribution Source
Annual probability of progression from MCI to AD by CSF biomarker scorea [19]
Low-risk group 0.064 0.01–0.16 Beta (2.46, 35.93)
Intermediate-risk group 0.108 0.03–0.22 Beta (4.05, 33.48)
High-risk group 0.244 0.17–0.33 Beta (27.89, 86.40)
Prevalence of MCI patients by risk levels [19]
Low-risk group 0.6
Intermediate-risk group 0.2
High-risk group 0.2
Annual transition probability [40, 79]
Stage to stage (AD)
Mild to moderate 0.167 0.156–0.178 Beta (690.43, 3443.86)
Mild to severe 0.014 0.010–0.018 Beta (59.63, 4199.86)
Moderate to severe 0.299 0.286–0.312 Beta (1355.02, 3176.83)
Community to nursing home
Mild AD 0.012 0–0.028 Beta (2.27, 186.70)
Moderate AD 0.034 0–0.069 Beta (3.57, 101.46)
Severe AD 0.066 0.005–0.128 Beta (3.74, 52.91)
Excess mortality due to AD (additive effect)b 0.11 0.055–0.165 [53, 54]
Treatment effectiveness (RR)
MCI patients 0.84 0.70–1.02 Lognormal (-0.17, 0.096) [36]
AD patients
Mild to moderate 0.58 0.35–0.76 Lognormal (-0.55, 0.198) Estimated by authors
Moderate to severe 0.95 0.64–1.41 Lognormal (-0.05, 0.114) [42]
Treatment harm
Annual prob. of AE (control) 0.23 0.2–0.26 Beta (173.78, 581.77) [43]
AEs in MCI (RR) 1.09 1.02–1.16 Lognormal (0.086, 0.033) [36]
AEs in AD (RR) 2.09 1.81–2.40 Lognormal (0.736, 0.073) [44]
Withdrawal due to AEc 0.18 0.13–0.22 Beta (41.67, 181.76) [44]
Withdrawal due to non-AE in MCI 0.046 0.035–0.058 Beta (52.94, 1201.7) Assumed
Withdrawal due to non-AE in AD 0.11 0.10–0.12 Beta (190.03, 1543.9) Assumed
Health utility
MCI 0.73 0.58–0.88 Beta (23.86, 8.82) [27, 80]
AD [49]
Mild
Community 0.68 0.54–0.82 Beta (28.34, 13.34)
Nursing home 0.71 0.57–0.85 Beta (27.97, 11.42)
Moderate
Community 0.54 0.43–0.65 Beta (42.08, 35.85)
Nursing home 0.48 0.37–0.59 Beta (37.59, 40.72)
Severe
Community 0.37 0.29–0.45 Beta (67.3, 114.6)
Nursing home 0.31 0.24–0.38 Beta (51.72, 115.11)
AEd 0.95 0.916–0.976 Beta (190, 10) [29]
Lumbar punctured 0.01 0.009–0.012 Beta (9800, 99) Assumed, [52]
Cost (US$, per person-year)
MCI 7467 3733–11,200 Gamma (15.36, 0.0021) [56]
Formal [55]
Mild AD
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hazard model for the best combination of CSF biomarker.
The three risk groups were defined by the quintiles of the
multi-biomarker score: high risk (the 3rd, 4th, and 5th
quintiles), intermediate risk (the 2nd quintile), and low risk
(the 1st quintile). We calculated the cumulative probability
of progression to AD for each risk group using the Kaplan–
Meier survival functions. For each risk group, we con-
verted the 6-year cumulative probability into an annual
probability of progression to AD (conditional on still being
in the MCI state) and used this annual probability in our
decision model, assuming a constant probability over the
6 years.
For transitions among AD stages, we used probabilities
estimated by Spackman et al., who analyzed data from the
Uniform Data Set of the National Alzheimer Coordinating
Center [40]. They reported estimated probabilities of stage-
to-stage transitions and probabilities of community-to-
nursing-home transitions conditional on AD stage. Based
on the rule of conditional probability, we calculated the
combined stage and nursing home transition probabilities
(e.g., moving from mild AD community setting to mild AD
nursing home) by multiplying these two transition proba-
bilities together. We assumed that the risk of transitioning
from community to nursing home conditional on AD stage
is as reported and does not change for those persons who
progress to different AD stages within the year.
2.3.2 Treatment Effectiveness
A recent Cochrane review [36] reported the relative risk
(RR) of progression to dementia as 0.84 (95% CI
0.70–1.02) over 3 years (although effects for year 1 and
year 3 were borderline significant) in MCI patients treated
with a ChEI. Namely, it represents a 16% reduction of the
annual progression risk from MCI to AD. In our base-case
analysis we assumed that the effect persisted for only the
first 3 years of treatment based on the synthesized results
of the review.
Table 1 continued
Parameter Mean 95% CI Distribution Source
Community 9380 4690–14,070 Gamma (15.37, 0.0017)
Nursing home 50,865 25,432–76,297 Gamma (15.37, 3.06)
Moderate AD
Community 13,859 6929–20,788 Gamma (15.37, 0.0011)
Nursing home 55,362 27,681–83,043 Gamma (15.37, 2.81)
Severe AD
Community 20,889 10,445–31,334 Gamma (15.37, 7.46)
Nursing home 59,327 29,664–88,991 Gamma (15.37, 2.63)
Informal [55]
Mild AD
Community 11,876 5938–17,815 Gamma (15.37, 0.0013)
Nursing home 1267 633–1900 Gamma (15.33, 0.0127)
Moderate AD
Community 20,559 10,279–30,838 Gamma (15.37, 7.58)
Nursing home 973 486–1459 Gamma (15.35, 0.016)
Severe AD
Community 20,724 10,362–31,086 Gamma (15.37, 7.52)
Nursing home 1028 514–1542 Gamma (15.33, 0.0151)
Drug (donepezil) 2884 1442–4325 Gamma (15.35, 0.0054)) AWP, [57]
Office visit due to treatment (per time) 83 42–125 Gamma (14.88, 0.1837) [49]
CSF biomarker testing (per person) 324 162–487 Gamma (15.50, 0.0492) [25]
AD Alzheimer’s disease, AE adverse event, AWP average wholesale price, CI confidence interval, CSF cerebrospinal fluid, MCI mild cognitive
impairment, RR relative risk
a CSF biomarker scores were calculated by the equation: (-0.006) 9 Ab1–42 ? 0.012 9 P-tau181p [19]. The three risk groups were defined by
the quintiles of the scores: high risk (the 3rd, 4th, and 5th quintiles), intermediate risk (the 2nd quintile), and low risk (the 1st quintile). Annual
transition probability of each risk group was converted from the 6-year cumulative probability estimated by the Kaplan–Meier survival functions
b Applied only to patients with severe AD and half of this to patients with moderate AD. We assumed MCI patients and patients with mild AD
have the similar background all-cause mortality rate in terms of age
c Annual probability derived from 6-month data by the exponential function (0.18 = 1 - exp[-0.0964 9 2])
d Incorporated as disutility due to the treatment or lumbar puncture
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The effectiveness parameter of ChEI treatment applied
to patients with moderate AD was derived directly from an
RCT [42], but we computed the RR for patients with mild
AD using the data provided in the same RCT due to lack of
directly applicable information. The RRs were 0.58 (95%
CI 0.35–0.76) and 0.95 (95% CI 0.64–1.41) for patients
with mild AD and moderate AD, respectively. In other
words, mild AD patients treated with ChEIs experience a
42% reduction in the annual risk of transitioning to either
moderate or severe AD, whereas the reduction was 5% for
moderate AD patients receiving treatment transitioning to
severe AD.
2.3.3 Adverse Events (AEs) Associated with Treatment
We used the result from a systematic review [43] for the
annual risk of AEs (0.23) in the placebo arm of donepezil
trials for MCI patients as the baseline risk for both MCI
and AD patients receiving no treatment in our model. The
reported RR of overall AEs between the treatment and the
control groups for MCI patients was 1.09 (95% CI
1.02–1.16) [36]. For AD patients, we converted the
reported odds ratio (OR) [44] to RR using methods from
the Cochrane Handbook [45]. The converted RR was 2.09
(95% CI 1.81–2.40).
Despite a low frequency of complications for lumbar
puncture [46], such as post-lumbar puncture headache,
especially in the elderly population [47, 48], we took into
account AEs due to CSF biomarker testing in the present
study.
2.3.4 Withdrawal of Cholinesterase Inhibitor (ChEI)
Treatment
We assumed that if patients discontinued treatment, they
would experience the same risks of transitioning to the next
health state as untreated patients. We did not assume any
residual effects of treatment. In addition, MCI patients who
discontinued the treatment would not be subsequently
treated, even though they converted to AD. A systematic
review [44] of 10 RCTs examining the efficacy of ChEIs
among AD patients showed that more patients discontinued
therapy due to AEs in the treatment group (18%) than in
the placebo group (8%) within a study period of 6 months
for all but two studies. We derived an annual withdrawal
probability of 18% (95% CI 13–22%) conditional on
experiencing an AE. Due to data availability, we applied
this annual probability derived from AD patients to MCI
patients as MCI is considered as the prodromal stage of AD
[5] and the medication considered in the present study is
one of the ChEIs. We also calculated the annual probability
of withdrawal from treatment due to other reasons (ex-
cluding AEs) as 4.6% (95% CI 3.5–5.8%) and 11% (95%
CI 10–12%) for MCI and AD patients receiving treatment,
respectively.
2.3.5 Health Utilities
We assigned health-related quality-of-life weights to dis-
ease severity and residential settings based on analyses by
Neumann et al. [49, 50], because it was one of the few
studies that estimated health utilities for joint states
defined by disease severity and residential settings. In the
study, they acquired quality-of-life weights, stratified by
disease stage and setting, using the Health Utilities Index
Mark II (HUI:2), which was administered in a companion,
cross-sectional study of 528 caregivers of AD patients in
the US [50]. Caregivers were asked to answer the ques-
tionnaire as the proxy respondents. Later, the responses to
the questionnaire were converted into preference weights
using the HUI:2 multi-attribute utility function [51]. Due
to the absence of a range of quality-of-life weights by
residential settings reported in their study, we applied the
estimates of the standard error for AD patients dwelling
in the community to AD patients in the nursing home. In
addition, we also accounted for the quality-of-life decre-
ment resulting from AEs due to the treatment, which was
specified at 0.05 [29] as long as the treatment was pro-
vided. This disutility was accounted for by multiplying
the assigned utility for each relevant state (e.g., MCI,
mild AD, or moderate AD) by 0.95. The one-time disu-
tility of 0.01 following the lumbar puncture (for CSF
biomarker testing) was derived from the literature where
the assumption was made [52].
2.3.6 Excess Mortality
The annual excess mortality rate among patients with
severe AD was estimated at 0.11 by the additive model
[53, 54]. We assumed that patients with moderate AD
would experience half of the excess rate (i.e., we added
0.055 to the background death rates for patients in the
moderate AD stage) and tested this assumption with a
multiplier (range 10–90%) of excess mortality in the sen-
sitivity analysis. We assumed that this additive effect is the
same regardless of the patients’ age or gender [53]. We
assumed that the mortality rate for patients in the MCI and
mild AD stage is equal to the background all-cause mor-
tality rate.
2.3.7 Costs
We took a modified US societal perspective to include
medical costs, and time costs of informal caregiving in the
CEAs. In addition, the healthcare sector perspective (in-
formal costs excluded) was also considered.
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Formal and informal careWeused the cost estimates reported
by Leon et al. [55] for patients with AD based on severity and
residential (community or nursing home) setting. These costs
include both formal (paid health services) and informal care
(defined as paid and unpaid services) for AD patients, where
informal costs were estimated by replacement wages. We
converted monthly costs to annual costs to assign to the rel-
evant health states in our model. Because the variance (95%
CI) of costs was not reported in the study, we assumed that the
cost estimate for each health state in themodelwas 50% lower
or higher from themean of point estimates for the lower bound
and the upper bound, respectively.
For the costs incurred in the MCI stage, we used data from
Leibsonet al. [56] to inform formal healthcare costs, including
medical costs, pharmaceuticals, and informal healthcare costs
(home care, assisted living, and transport) for MCI patients.
We did not account for the non-healthcare direct costs
resulting from the loss of productivity of patients due to
disease progression because we targeted the 65-year-old
population. The CEA results presented included both for-
mal and informal costs unless specified.
Medication We based the unit costs for AD medications on
the average wholesale price reported in the Red Book [57].
The daily costs for these drugs were calculated based on
their recommended dose and usage from the licensed
labels. Because the drug is currently off-patent, we derived
the medication cost at the available market price (US$7.79)
per day (the cost for donepezil 5 mg is the same as 10 mg)
and the largest pack size. We estimated the annual drug
costs as 365.25 9 US$7.79 = US$2845. For the follow-up
cost due to the treatment, we continued the assumption
made by a previous study [49] that donepezil would induce
two and one extra office visits every year along with the
treatment effect duration for MCI and AD patients,
respectively. One office visit was associated with US$82 as
estimated by the previous study [49].
CSF biomarker testing The cost of CSF biomarker analy-
sis, a one-time cost per patient, was estimated using the
cost data from Centers for Medicare and Medicaid Services
hospital outpatient fee schedule [25].
Because the ChEI treatment-induced AEs are generally
mild or moderate [36, 58], we did not consider the costs of
treating AEs but the disutility associated with those AEs.
All cost estimates were inflated to 2016 US dollars using
the Consumer Price Index [59] if needed.
2.4 Analyses
2.4.1 Base-Case Analysis
We calculated expected discounted lifetime costs and dis-
counted QALYs, generated from the probabilistic
sensitivity analysis (PSA) to account for the nonlinear
feature of Markov models [60, 61], for each of the six
strategies with the best estimates for all of the input
parameters and preferred set of assumptions. Results were
presented as incremental cost-effectiveness ratios (ICERs),
measured as the additional cost per additional QALY
gained. The most effective strategy with an ICER that is
below the designated willingness-to-pay (WTP) threshold
(i.e., the ratio of US$100,000 per QALY suggested by
Neumann et al. [62] in the US setting) would be declared as
a cost-effective strategy. After the cost-effective strategy
was decided, we further calculated its ICER in the 2.5th
and 97.5th percentiles using the same PSA results men-
tioned above.
2.4.2 Sensitivity Analysis
We conducted deterministic sensitivity analyses and PSA
to evaluate uncertainty with respect to all the parameters
included in the simulation models. Table 1 presents the
parameter values and their corresponding distributions.
To ensure only meaningful scenarios, we required that
the rank order of QALY weights in each PSA iteration
was aligned with disease severity and residential settings
[63], which implied that the health utility of
u(MCI)[ u(mild AD)[ u(moderate AD)[ u(severe
AD) and u(community)[ u(nursing home), applying the
preference-ordering algorithm developed by Goldhaber-
Fiebert and Jalal [64]. We presented PSA results using
the cost-effectiveness acceptability curve (CEAC) [65],
and further plotted the cost-effectiveness acceptability
frontier (CEAF) [66, 67] on the top of CEAC to
simultaneously present the optimal strategy and the level
of uncertainty associated with that strategy at different
WTP thresholds.
2.4.3 Scenario Analysis
We conducted the scenario analysis, assuming patients are
allowed to receive treatment in the AD stage even if they
were treated in the MCI stage, because this is the standard
of care, even though the effectiveness of MCI treatment is
unclear. Because it is not known whether treatment effec-
tiveness for AD is the same for treated and untreated MCI
patients, we further examined diminished treatment effec-
tiveness in the AD stage for treated MCI patients. For
untreated MCI patients, the treatment effectiveness in the
AD stage was held constant at the base-case value (RR
0.58).
All analyses were performed in TreeAge Pro 2016
(TreeAge Software, INC, Williamstown, MA, USA), and
Microsoft Excel (Microsoft Corp., Redmond, WA, USA).
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3 Results
3.1 Base-Case Analysis
Table 2 shows discounted costs and discounted QALYs
for each strategy (the disaggregated total costs and
QALYs by health states for each strategy is presented in
Appendix A and B, respectively. In addition, we sum-
marized the costs of medication, office visits, and CSF
biomarker testing separated from total costs by disease
stages and settings in Appendix C, see electronic sup-
plementary material [ESM]). The most effective and most
costly strategy was to test and treat MCI patients at low
risk, which resulted in an ICER of US$37,700 per QALY
compared with not testing and not treating any MCI
patient. The ICERs for this strategy at the 2.5th and
97.5th percentiles were US$18,900 and US$50,100 per
QALY, respectively. In addition, results indicated that
testing and treating patients at low risk was still the most
cost-effective strategy with an ICER of US$59,800 per
QALY from a healthcare sector perspective (see Appen-
dix D and E for disaggregated costs results in the ESM).
3.2 Deterministic Sensitivity Analysis
Table 3 summarizes the selected one-way sensitivity
analysis results with ICERs and corresponding comparators
for the key parameters (see Appendix F in the ESM for
results with the remaining parameters). Our base-case
results were most sensitive to variations in the effective-
ness of treatment. For example, if the treatment effective-
ness for mild AD patients was better than our base-case
estimate, or the treatment effectiveness for MCI patients
was worse than our base-case estimate, then no testing and
no MCI treatment would be cost-effective. Our results were
also sensitive to the health utility assigned to patients in the
MCI stage. The cost of medication (donepezil) had little
impact on our base-case results.
3.3 Probabilistic Sensitivity Analysis
Figure 2 shows the CEAC and the CEAF generated from our
PSA. With the maximized expected outcomes shown in the
base-case analysis, the strategy of testing and treating MCI
patients at low risk showed a 26% probability of being cost-
effective at aWTP of US$100,000 per QALY, whereas it was
30% for no testing and noMCI treatment. Testing and treating
MCI patients at low risk was the strategy with the highest
probability of being cost effective (29%) for a WTP of
US$150,000perQALY. Strategies of testing and treating high
risk, and testing and treating high or intermediate risk showed
a lower likelihood of cost-effectiveness compared with other
test-and-treat strategies. They were less likely to be cost-
effective whenWTP was higher than US$30,000 per QALY.
3.4 Scenario Analysis
As expected, QALYs increasedwith the increasing number of
treatedMCI patients and the strategy of no testing and treating
all MCI patients was associated with the highest cost and
highest QALYs, with an ICER of US$27,600 per QALY,
given the relaxed assumption that patients are allowed to
receive treatment in the AD stage even if they were treated in
theMCI stage.All of the testing strategieswere either strongly
or weakly dominated. In addition, results of examining the
diminished AD treatment effectiveness for treated MCI
patients and a constant AD effectiveness for untreated MCI
patients indicated that the strategy of no testing and treating all
MCI patients remained the best strategy when the RR of the
treatment effectiveness for AD was not worse than 0.65 at a
WTP threshold of US$100,000 per QALY (not shown).
4 Discussion
In this study, we sought to evaluate the potential value of
using CSF biomarkers to target treatments, based on the
best available data, for a subset of MCI patients according
Table 2 Base-case results (per
patient) of performing CSF
biomarker testing and
subsequently treating MCI
patients based on their risk
levels of progression to AD
Strategy Cost (US$) QALYs ICER (US$/QALY)a
Test and treat high or intermediate risk 270,593 7.471
Test and treat high risk 270,735 7.475 Weakly dominated
No testing and treat all MCI patients 271,083 7.509 12,800
No testing and no MCI treatment 275,302 7.627 Weakly dominated
Test and treat low or intermediate risk 276,286 7.647 Weakly dominated
Test and treat low risk 276,428 7.651 37,700
If patients received treatment in the MCI stage, no treatment would be provided when they convert to AD
AD Alzheimer’s disease, CSF cerebrospinal fluid, ICER incremental cost-effectiveness ratio, MCI mild
cognitive impairment, QALYs quality-adjusted life-years
a The value was rounded to the nearest $100. A weakly dominated strategy is a strategy with a higher
ICER than a more costly strategy
T. L. Michaud et al.
Table 3 Incremental cost-effectiveness ratios of one-way sensitivity analysis results with key parameters
Analysisa Test-and-treat strategy
Test and
treat low
risk
Test and treat
low or
intermediate
risk
No test and
no MCI
treatment
No test
and treat
all MCI
Test and
reat high
risk
Test and treat
high or
intermediate
risk
Base-case 37,700b Weakly DOM Weakly DOM 12,800c Weakly DOM –
Annual probability of progression from MCI to AD
At low risk, 1% 38,500b Weakly DOM Weakly DOM 19,000c Weakly DOM –
At low risk, 16% Weakly DOM Weakly DOM 35,600b – Weakly DOM Weakly DOM
At intermediate risk, 3% Weakly DOM 40,700b Weakly DOM 20,400c – Weakly DOM
At intermediate risk, 22% 38,100b Weakly DOM Weakly DOM 9400c Weakly DOM –
At high risk, 17% 64,400d Weakly DOM 36,200b 9500c Strongly DOM –
At high risk, 33% 64,400d Weakly DOM 38,000b 9500c Strongly DOM –
Treatment effectiveness (RR)
Mild AD, 0.35 Strongly DOM Strongly DOM 16,400e Strongly
DOM
7500c –
Mild AD, 0.76 Strongly DOM 438,000b Strongly
DOM
5800c Strongly DOM –
Moderate AD, 0.64 199,000d Strongly DOM 27,800b 8800c Weakly DOM –
Moderate AD, 1.41 64,400d Weakly DOM 37,300b 9500c Strongly DOM –
MCI patients, 0.70 Strongly DOM 131,800b Strongly
DOM
– Strongly DOM Strongly DOM
MCI patients, 1.02 Strongly DOM Strongly DOM 10,300e Strongly
DOM
– Strongly DOM
Treatment harm
Annual prob. of AE (control), 20% 75,300d Strongly DOM 34,400b 9300c Strongly DOM –
Annual prob. of AE (control), 26% 65,200d Weakly DOM 36,600b 9600c Strongly DOM –
AEs in MCI (RR), 1.02 69,600d Weakly DOM 37,500b 8600c Strongly DOM –
AEs in MCI (RR), 1.16 64,700d Weakly DOM 33,300b 10,200c Strongly DOM –
AEs in AD (RR), 1.81 79,200d Strongly DOM 33,400b 9400c Strongly DOM –
AEs in AD (RR), 2.40 Strongly DOM Strongly DOM 10,200b Strongly
DOM
– Strongly DOM
Withdrawal due to AE, 13% 78,700d Strongly DOM 44,500b 7500c Strongly DOM –
Withdrawal due to AE, 22% 64,800d Weakly DOM 35,600b 10,700c Weakly DOM –
Health utility
MCI patients, 0.58 995,200d Strongly DOM 26,500e Weakly DOM 15,400c –
MCI patients, 0.88 Strongly DOM 52,800b Weakly DOM 6200c Strongly DOM –
Health utility
AE, 0.916 53,500f 53,000d 44,900b 8600c Strongly DOM –
AE, 0.976 84,900d Strongly DOM 31,700b 10,300c Strongly DOM –
Lumbar puncture, 0.009 78,600d Strongly DOM 35,500b 9000c Strongly DOM –
Lumbar puncture, 0.012 61,300d Weakly DOM 37,300b 9700c Strongly DOM –
Annual costs
MCI, US$3733 72,100d Strongly DOM 35,500b 8600c Strongly DOM –
MCI, US$11,200 67,800d Weakly DOM 35,500b 10,200c Strongly DOM –
Formal costs for patients dwelling in the community
Mild AD, US$4690 96,600d Strongly DOM 14,300e Weakly DOM – Strongly DOM
Mild AD, US$14,070 95,400f 60,400b Strongly
DOM
– Strongly DOM Strongly DOM
Moderate AD, US$6929 59,100d Weakly DOM 42,100b 4400c Strongly DOM –
Moderate AD, US$20,788 80,400d Weakly DOM 28,900b 14,500c Weakly DOM –
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to their risk level of progression to AD. Our results indi-
cated that testing and treating patients at low risk was cost-
effective with an ICER of US$37,700 per QALY, which
was more beneficial than treating patients at high risk,
although such a practice would be contradictory to the
widely held belief that interventions should usually be
aimed at high-risk patients. However, the low-risk patients
in our case were not comparable to the low-risk patients in
the general population. They were instead low-risk patients
among the MCI population—that is, referred to specialty
Table 3 continued
Analysisa Test-and-treat strategy
Test and
treat low
risk
Test and treat
low or
intermediate
risk
No test and
no MCI
treatment
No test
and treat
all MCI
Test and
reat high
risk
Test and treat
high or
intermediate
risk
Severe AD, US$10,445 53,900f 47,000b Weakly DOM 1300c Strongly DOM –
Severe AD, US$31,334 78,600d Weakly DOM 36,100b 21,500e 7400c –
Formal costs for patients dwelling in a nursing home
Mild AD, US$25,432 75,900d Weakly DOM 26,800b 17,600e 10,700c –
Mild AD, US$76,297 57,000d Weakly DOM 45,300b 3400c Strongly DOM –
Moderate AD, US$27,681 62,800d Weakly DOM 38,200b 8700c Strongly DOM –
Moderate AD, US$83,043 70,800d Weakly DOM 35,200b 9900c Strongly DOM –
Severe AD, US$29,664 62,500f 49,700b Weakly DOM 1600c Strongly DOM –
Severe AD, US$88,991 88,700d Weakly DOM 22,700e Weakly DOM 2400c –
Excess mortality in moderate AD
Multiplier, 10% 74,700d Weakly DOM 26,200b 20,800e 6200c –
Multiplier, 90% 57,800d Strongly DOM 44,600b 2200c Strongly DOM –
The comparator strategy for the calculation of ICERs was varied by the value of parameters tested
AD Alzheimer’s disease, AE adverse event, DOM dominated, ICERs incremental cost-effectiveness ratios, MCI mild cognitive impairment, RR
relative risk
a The value was rounded to the nearest $100. – indicated the reference strategy. A weakly dominated strategy is a strategy with a higher ICER
than a more costly strategy, and a strongly dominated strategy is a strategy that is more costly but less effective
b Compared with no testing and treat all MCI patients
c Compared with test and treat high or intermediate risk
d Compared with no testing and no MCI treatment
e Compared with test and treat high risk
f Compared with test and treat low or intermediate risk
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Fig. 2 Cost-effectiveness
acceptability curve showing the
probability that a strategy is
cost-effective at various
willingness-to-pay thresholds.
Vertical lines represent the
incremental cost-effectiveness
ratio for strategies of ‘no testing
and treat all MCI patients’
(US$12,800/QALY), and ‘test
and treat low risk’ (US$37,700/
QALY). CEAF cost-
effectiveness acceptability
frontier, MCI mild cognitive
impairment, QALYs quality-
adjusted life years
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clinics—and thus have a higher risk of progression to AD
than the general population. Thus, the conventional ratio-
nale (targeting high-risk patients) might not be applicable
in our case. Moreover, this finding may be associated with
our assumption that treated MCI patients were ineligible
for treatment if they converted to AD, and that MCI
patients at higher risk faced a relative short time until
clinical diagnosis of AD in our model [68, 69]. As a result,
the trade-off between treatment effectiveness for MCI
patients and for patients with mild AD was a key driver of
this finding. With the more conservative assumption of
treatment effectiveness for MCI patients utilized here when
compared with other published models using a hypothetical
DMT(RR 0.5) [29, 30, 70, 71], our finding may provide a
more realistic picture of potential treatment effectiveness
for MCI and AD patients.
Another possible explanation for the study finding is that
treatment duration for MCI patients at high risk may be
truncated (as we assumed the maximum treatment period
was 3 years based on the available evidence) due to the
conversion to AD. However, with results showing that time
in MCI stage (without intervention) was 3.16, 6.48, and
8.67 years for patients at high, intermediate, or low risk,
respectively, and a constant probability of transitioning
from MCI to AD for high-risk patients was 0.244 annually,
the treatment duration was less likely to be truncated at
Year 3 for this group. It is also possible that the treatment
response varied by MCI patients’ CSF biomarker profiles
(i.e., patients at high risk had a better response to the ChEI
therapy than patients at intermediate or low risk). By
assuming that MCI patients at high, intermediate, and low
risk had 100%, 80%, and 60% response to ChEI treatment,
respectively, results of additional analyses indicated that no
testing and no MCI treatment was cost-effective with an
ICER of US$30,000 per QALY, while it was US$106,300
per QALY for treating patients at low risk (results not
shown).
As indicated in the study by Sko¨ldunger et al. [31],
patients will live longer as a consequence of the treatment,
and in turn accrue higher costs if providing treatment in the
AD stage but not in the MCI stage. In our case, the strategy
of ‘no testing and no MCI treatment’ reflected highest costs
in the mild AD stage (due to the treatment costs and longer
period in the mild AD stage, Appendix G, see ESM) but
lowest costs in the moderate and severe AD stage. This
may be explained by (1) a great difference between the
treatment effectiveness for mild AD (RR 0.58) and mod-
erate AD (RR 0.95), which implies that there is almost no
treatment effect for moderate AD; (2) the time difference
in the states (Appendix G, see ESM); and (3) age- and
disease severity-related mortality rates. In this strategy,
simulated patients were older when they progressed to
moderate AD (6.285 QALYs in the MCI and mild AD
stage), and thus with higher mortality rates, compared with
the relatively younger population (6.023 QALYs in the
MCI and mild AD stage) in the strategy of ‘no testing and
treat all MCI patients’. Moreover, due to the modest
treatment effectiveness for moderate AD, simulated
patients with moderate AD either progressed to severe AD
or death quickly. In addition, our findings are in line with
the Sko¨ldunger et al. study [31] oppositely with more time
in the MCI stage and less time in the AD stage as a whole
(the condensing effect) when treating MCI but not AD (no
testing and treat all MCI patients).
It is of value to investigate the feasibility of the treat-
ment continuum from MCI to AD stages. Not surprisingly,
the scenario analysis where treatment was allowed in both
MCI and AD stages produced greater benefits than when
treatment was only allowed in one or the other. This
implied that alternative interventions that allowed for the
effectiveness to be carried over from MCI to AD stages
would be considered as an optimal strategy. Furthermore,
sensitivity analyses with a diminished AD treatment
effectiveness for treated MCI patients and a constant
effectiveness for untreated MCI patients indicated that no
testing and treating of all MCI patients was cost-effective if
the AD effectiveness for treated MCI patients was not
worse than RR 0.65.
Although previous studies concluded that CSF bio-
marker testing could allow one to identify MCI patients
who are best suited for potential pharmacological treatment
[19], this study suggests that treating low-risk MCI patients
might lead to a greater benefit by slowing the progression
to AD. That is to say, clinicians or policy makers might
consider the potential to intervene not only on higher-risk
patients but on low-risk MCI patients when they initiate the
disease management plan. Moreover, with the plausibility
that MCI patients at high risk may be close to the threshold
of AD diagnosis and that MCI patients in general are at a
higher risk for progression than the general population, the
findings again suggest that the MCI population might
benefit greatly from early intervention with the use of CSF
biomarker testing from a cost-effectiveness perspective.
Further studies are needed to re-evaluate the benefits of
early detection or diagnosis when the DMT is available.
It is possible that the most cost-effective (optimal)
strategy may not have the highest probability of being cost-
effective [67]. In our case, the strategy of testing and
treating patients at low risk was most cost-effective in the
base-case analysis; however, its probability of being cost-
effective in the PSA was only 26% at a WTP of
US$100,000 per QALY. The results showed that there is a
high degree of decision uncertainty surrounding the opti-
mal strategy in the present study even with the best
available evidence. In this case, the decision of whether to
treat MCI patients or not may benefit from conducting
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value of information analysis to assess the potential gains
to further research [72] such as gathering more information
on the key parameters (i.e., the treatment effectiveness for
MCI), before making a decision. However, there is a trade-
off between the potential gain for more research and the
concurrent consequences (loss of potential benefits from
early interventions) of not taking any action.
Our study has several limitations. Our modeling results
were heavily subject to the inconclusive findings of treat-
ment effectiveness. The treatment effectiveness of ChEIs
for MCI patients was derived from a recent Cochrane
review study [36] where authors reported evidence of
minor benefits (effects for year 1 and year 3 were border-
line significant; effects for year 2 were significant) with
limitations and uncertainty, and further concluded that
ChEI treatment is not recommended for MCI patients due
to weak evidence. Compared with other similar studies
using a hypothetical treatment effectiveness (RR 0.5)
[29–31, 70, 71, 73], however, our assumption was rela-
tively conservative (RR 0.84) and was based on point
estimates reported from the most recent review evidence.
Moreover, by applying the empirical data, our approach
should better reflect what the real potential treatment
benefits might be, acknowledge the debate of whether we
should treat MCI patients or not based on the current evi-
dence, and reflect that if a decision must be made, it should
be made based on the available evidence [38].
No recent meta-analyses of treatment effectiveness for
AD patients were presented as the measure of the RR,
which was built-in in our model to reflect the treatment-
associated reduction on the risk of progression between the
AD stages. Most studies [44, 74, 75] reported the effect
size of this parameter as the point difference of cognitive
tests, such as Mini-Mental State Examination (MMSE) or
the AD and Associated Disorders Cognitive Scale between
treatment and control arms instead of the risk reduction of
transitions to more severe stages of AD (presented as the
RR). Hence, we applied the information from point dif-
ferences of MMSE scores along with the proportion of
patients with mild AD and moderate AD in an RCT to
indirectly derive the RR of progression from the mild to
moderate AD stage for the treatment group versus the
control group.
The cost information [55] applied in this study is out-
dated due to the unavailability or inapplicability of recent
data. Changes in many social and cultural factors are very
likely to influence the cost estimates. However, we found
that our base-case findings were robust under wide ranges
of cost estimates examined in sensitivity analyses.
We were not able to account for the possible double
treatment effects, which may lead to a potential bias of
the study findings, resulting from the treatment effect
embedded in the estimated transition probabilities derived
from the scholarly literature where about 70% of their
analysis sample were reported using AD medication.
However, the cost-effectiveness metrics (ICERs) were the
relative difference between the different test-and-treat
strategies in terms of accrued costs and QALYs. In this
case, the treatment effects should be compensated or
minimal, which should not have major impact on our
findings.
We acknowledge several limitations, such as solely
using cognition as a driver of disease progression or a
limited number of health states to present the natural his-
tory of disease due to the use of Markov modeling tech-
niques [76, 77] existing in the current simulation models in
AD. However, to build a model including indicators other
than cognitive function would increase the complexity of
the model structure, the trade-off between the complexity
and transparency of a simulation model should be well
balanced. The merit of using Markov models is that they
provide a relatively transparent analysis and accessibility
when compared with other models, such as discrete-event
simulation models, which may induce overspecification
where models may become more complex than necessary
(as a result of computational challenges) to elicit accurate
results [78].
We included a subset of all possible test-and-treat
strategies in the CEA. Our rationale is that we attempted to
find a threshold of CSF biomarker levels (a positive and
ordinal association with risk levels of AD) that would
decide which subset of MCI patients to treat from a cost-
effectiveness perspective. Therefore, it would not be logi-
cal to include strategies of ‘treat MCI patients at interme-
diate risk only’ or ‘treat MCI patients at low or high risk’ in
the CEA due to the ordinal nature of the risk levels.
Moreover, results of additional analyses including these
two strategies indicated that they were both weakly dom-
inated strategies.
For the transitions in the residential settings, we
assumed once AD patients enter a nursing home they
would remain in the institution until death. This may not
reflect the current practice that patients transition among
hospitals, home, and long-term care facilities within a short
period of time. However, in our case, most of the patients
who entered the nursing facility had severe AD. Accord-
ingly, given the similar disease severity, the accumulative
healthcare costs of staying in the nursing facility should be
similar to the transitions among hospitals, home or long-
term care facilities within the same periods of time from a
social perspective.
We acknowledge that using CSF biomarkers only to
categorize MCI patients into different risk levels of pro-
gression to AD may omit the potential added values from
including other risk factors, such as patient demographics
and their clinical characteristics.
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5 Conclusion
Based on the best available evidence regarding treatment
effectiveness for MCI, this study suggests that performing
CSF biomarker testing for early targeted treatments among
MCI patients may be cost-effective. Interpretation of these
results should be made with caution. Further research is
needed to reduce the high degree of uncertainty regarding
testing and treating MCI patients.
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